Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Shares in Pfizer ($PFE) inched higher early Tuesday even as the U.S. pharma giant forecast 2026 earnings that are below Wall ...

Pfizer has pursued deals of all sizes to build new revenue streams, but the outlook underscores that those investments are ...

Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.

Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

Pfizer’s shares, after a year of modest growth, recently fell following a cautious outlook for 2026, emphasizing ongoing ...

Pfizer (NYSE:PFE) shares slid about 5% on Tuesday morning after the company lowered its earnings and revenue forecasts for ...

Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

In a surprising turn of events, Pfizer has adjusted its profit forecast for 2026, indicating a potential decline in earnings that falls short of Wall Street expectations. This announcement has raised ...